Decentralized trials startup Curebase scraps clinical operations business unit, narrows in on software platform

De­cen­tral­ized clin­i­cal tri­als start­up Cure­base has laid off many em­ploy­ees as the com­pa­ny scraps its clin­i­cal op­er­a­tions busi­ness to fo­cus on soft­ware, per a Thurs­day LinkedIn post from founder and CEO Tom Lem­berg.

Cure­base’s down­siz­ing and nar­rowed am­bi­tions come as the de­cen­tral­ized and hy­brid clin­i­cal tri­als space ad­justs to the re­open­ing of in-per­son tri­als and grow­ing pains fol­low­ing a rapid rise in sim­i­lar star­tups dur­ing the Covid-19 pan­dem­ic. Like oth­er vir­tu­al tri­al providers, Cure­base aimed to im­prove pa­tient en­gage­ment, part­ner with more physi­cians in the com­mu­ni­ty set­ting and en­hance tri­al di­ver­si­ty.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters